Novel, Achiral 4‑Nitroimidazole Compounds with Potent Antitubercular Activity

新型非手性4-硝基咪唑化合物具有强效抗结核活性

阅读:1

Abstract

4-Nitroimidazole compounds (delamanid and pretomanid) have been approved for the treatment of both drug-susceptible and drug-resistant forms of tuberculosis. Besides toxicity reported for these compounds, they are chiral molecules which must be separated into pure forms; thus reducing synthetic accessibility. Herein, we report the syntheses of easily accessed achiral 4-nitroimidazoles. These compounds were tested in vitro for antitubercular and cell toxicity properties. While 4-nitroimidazoles derivatized with hydrazide were generally inactive, replacing the hydrazide with tetrazole generally led to compounds with potent antitubercular activity. A good number of 4-nitroimidazole incorporating tetrazole compounds exhibited potent antitubercular activity, with two of them (7e, 0.24 μM, and 7q, 0.92 μM) showing MIC(90) values which are submicromolar and without displaying cell toxicity. These compounds show good metabolic stability in the presence of human liver microsomes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。